Results 171 to 180 of about 53,202 (260)

GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023. [PDF]

Pediatrics
Chu PY, Kelly A, Hennessy S, Vajravelu ME, Huang J, Amaral S.   +5 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8836-8846, October 2026.
ABSTRACT Aims To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. Materials and Methods This retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m2) initiated on tirzepatide against 50 age‐, sex‐ and BMI‐matched ...
Simon A. Berry, Iona R. Goodman, Eleanor McNally, Jackie Elliott, Ahmed Iqbal   +4 more
wiley   +1 more source

Beyond Glycemic Control: GLP-1RA-Based Therapies and Emerging Targets Beyond the Metabolic Axis. [PDF]

J Clin Med
Matuszewski W, Wołos-Kłosowicz K, Włodarczyk P, Waśniewska P, Modzelewski R, Górny JM, Szklarz M, Madeksza M, Juranek J.   +8 more
europepmc   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9054-9068, October 2026.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8905-8912, October 2026.
ABSTRACT Aim In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre‐marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed. This study aimed to describe real‐world use of semaglutide, including dose titration, discontinuation patterns and ...
Mie Dyberg Skandov, Katrine McLain Christensen, Dagmar Abelone Dalin, Janne Unkerskov, Andreas Brønden, Marie Lund, Mikkel Bring Christensen, Kristian Karstoft   +7 more
wiley   +1 more source

GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes. [PDF]

Hepatol Commun
Choi J, Mitchell G, Nguyen VH, Przybyszewski E, Song J, Carroll A, Michta M, Almazan E, Simon TG, Chung RT.   +9 more
europepmc   +1 more source

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8946-8954, October 2026.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source

Responses to GLP-1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data. [PDF]

Obesity (Silver Spring)
Mallette JH, Speed JS, Lirette ST, Moore D, Clemmer JS.   +4 more
europepmc   +1 more source

Συστηματική ανασκόπηση: Ο ρόλος των GLP-1RAs στην καρδιαγγειακή νόσο / Systematic review: The role of GLP-1RAs in CVD

Ιστορικό: Οι αγωνιστές του υποδοχέα της γλυκαγόνης-1 (GLP-1RA) είναι καθιερωμένοι παράγοντες μείωσης της γλυκόζης και απώλειας βάρους, ωστόσο το πλήρες καρδιαγγειακό τους δυναμικό παραμένει ασαφές. Σκοπός: Να συντεθεί τεκμηρίωση σχετικά με τις καρδιαγγειακές επιδράσεις των μακράς δράσης GLP-1RA, με έμφαση στις σοβαρές ανεπιθύμητες καρδιαγγειακές ...
openaire   +1 more source

Looking Beyond Glycaemic Control: Real‐World 12‐Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9166-9177, October 2026.
ABSTRACT Aims To evaluate the real‐world effectiveness, safety, and tolerability of the Omnipod 5 hybrid closed‐loop system in adults with type 1 diabetes (T1D) with a novel focus on cardiometabolic markers alongside diabetic eye disease and renal function. Methods A single‐centre, retrospective analysis of adults with T1D using Omnipod 5 was conducted.
Eleanor McNally, Iona Goodman, Rebecca Morris, John Maliekkal, Dalha Saeed, Hao Wei Tan, Simon Berry, Jackie Elliott, Ahmed Iqbal   +8 more
wiley   +1 more source